The Pharmaceutical Services Negotiating Committee has announced that the Department of Health and Social Care (DHSC) has granted final price concessions to
further items for the month of October 2021. This is the fourth list of price concessions for the month.
Contractors can find information on the first two batches of price concessions here, and learn about the process involved on PSNC's website.
A price concession only applies for the month in which it is granted. No additional prescription endorsement are required as the new price is automatically applied
by the NHS BSA to all items submitted for payment in the same month for which a price concession is granted.
PSNC is still working with the DHSC to agree further concessionary prices on other drugs reported to be unavailable at the stated October 2021 Drug Tariff price.
Check Pharmacy business website for the price concession lists.
The Pharmaceutical Services Negotiating Committee (PSNC) has challenged price concessions imposed by the Department of Health and Social Care (DHSC) on some
of the medicines.
It has raised concerns on the process for setting price concessions to senior government officials responsible for medicines supply, warning that the system is not
working in the current environment from a community pharmacy contractor perspective.
"When a new government takes over next week, this will be one of several urgent topics being raised by PSNC to new ministers, alongside the fuel price crisis,
inflationary pressures and winter pressures on pharmacy businesses," said PSNC.
The final update to August price concessions was announced yesterday taking the total concessions granted to a record 138 for August. PSNC said: "Of those, 99 were
in line with PSNC requests, but prices for 39 lines were imposed by the Department of Health and Social Care (DHSC): those impositions do not match the purchase
prices reported by contractors and the evidence of market prices which we passed on to DHSC. In particular, the final imposed prices of Apriprazole and Temazepam
tablets has generated a lot of concern amongst contractors due to the large variation between their reimbursement prices and purchase prices during the month of
August."
The price concession for Atorvastatin 80mg has been increased to £3.91 from the previously set £3.45 for prescriptions dispensed in July, the Community Pharmacy
England has said. The Department of Health and Social Care additionally introduced a concession price of £3.38 for Atorvastatin 20mg.
"In July, our Dispensing and Supply Team experienced an unusually high influx of reports from pharmacies struggling to acquire Atorvastatin 80mg tablets at the
listed Drug Tariff price," said CPE.
CPE requested a price concession early in the month. However, after extended discussions, an agreement on the price wasn't reached. Consequently, on July 31st, the
DHSC imposed a concession of £3.45.
Addressing enduring pharmacy concerns over the pricing, CPE intensified advocacy with DHSC. This endeavour resulted in the revision of the Atorvastatin 80mg tablet
concession price to £3.91 for prescriptions submitted and dispensed in July.
According to CPE, this adjusted price sufficiently covers costs as reported by the majority of pharmacy owners.
However, DHSC has refrained from modifying concessionary prices for the other two requested lines by CPE. DHSC communicated that their team's data collection for
July, employing real-time sales and volume data, was incongruent with the adjustment of these prices, CPE further said.
There has been a lot of coverage in the national and pharmaceutical press of the prices being charged to pharmacy owners for certain medicines.
Leaving aside the reasons for steep price rises, I have been asked on social media and elsewhere whether pharmacy owners can refuse to supply prescribed medicines
if they would make a significant financial loss.
Legal obligation
The first thing to point out is that the National Health Service Act 2006 imposes a legal duty on the Secretary of State and NHS England to make arrangements for
people to receive sufficient prescribed drugs.
These arrangements involve the publication of the Drug Tariff.
The Drug Tariff includes reimbursement prices or a method for determining prices. Various factors can be taken into account in determining reimbursement prices. The
Drug Tariff does not provide a pound for pound reimbursement for medicines that pharmacies supply on NHS prescriptions.
Department of Health and Social Care (DHSC) has increased the rate of discount deduction for generics from 17.52 per cent to 20 per cent.
The Drug Tariff for April 2023 will contain changes to the discount deduction arrangements for pharmacy contractors, which will include- all concession lines to be
considered as Group Items for Discount Not Deducted i.e. DND or zero discount (ZD) items; and rate of discount deduction for generics to increase from 17.52% to 20%
The Pharmaceutical Services Negotiating Committee (PSNC) and DHSC agreed on the changes for all concession lines to be considered as Group Items for Discount Not
Deducted. Therefore from 1 April 2023, a new category will be introduced into Part II of the Drug Tariff 'Drugs for which discount is not deducted'.
However, the committee had rejected the changes in the rate of discount deduction for generics. It said, "Following pressure from NHS England, Ministers have now
chosen to impose changes to the previously agreed discount deduction arrangements, which come into effect from 1 April, and will be kept under review."
Department of Health and Social Care (DHSC) has updated the final price concessions for June 2023, following a discussion by Community Pharmacy England
regarding medicine pricing issues reported by pharmacy owners (its members).
A price concession only applies for the month it is granted; any prices agreed for concessions requested late in the month will roll over into the following month.
Community Pharmacy England encouraged pharmacies to report any problems obtaining a Part VIII product at or below the stated Drug Tariff price, using the online
feedback form on the Community Pharmacy England website along with full details of the supplier and price paid for any products sourced above the Drug Tariff price.
The association will investigate the extent of the problem and, if appropriate, discuss the issue with DHSC.
Any prescription for Promethazine hydrochloride 10mg tablets x 56 submitted for payment to the NHSBSA for July 2022 will be reimbursed at the new price of
£17.77 not as per the price concession of £13.45 announced in the 4th concessions update published on 29 July 2022, said the Pharmaceutical Services Negotiating
Committee (PSNC).
In July 2022, PSNC received several reports from contractors unable to obtain Promethazine hydrochloride 10mg tablets (56) at the published Drug Tariff price of
£4.24.
Therefore, it submitted a request for a price concession, which was granted and subsequently published but this was later withdrawn after confirmation from the
Department of Health and Social Care (DHSC) that due to the price change mechanism, the reimbursement price for Promethazine hydrochloride 10mg tablets has
increased from £4.24 to £17.77 for July 2022.
PSNC said, "Following the price change mechanism rules, for generic drugs (excluding drugs in Category M), a price change up to and including the 8th of the month
takes effect for prescriptions dispensed in that same month. Any price change after the 8th takes place in the following month."
The Department of Health and Social Care (DHSC) has revised concession prices for four products and confirmed three further price concessions for May 2024.
This announcement comes in response to representations made by Community Pharmacy England (CPE) on behalf of community pharmacy owners
Concession prices have been redetermined for Ezetimibe 10mg tablets, Quetiapine 100mg tablets, Quetiapine 150mg tablets and Quetiapine 200mg tablets.
Here are the newly granted concessions:
Nicorandil 10mg tablets (60 tablets): £5.05
Nicorandil 20mg tablets (60 tablets): £9.30
Pregabalin 75mg capsules (56 capsules): £1.54
The revised prices will be applicable to prescriptions submitted for payment during the dispensing month of May 2024, and do not apply to June 2024 prescriptions,
the CPE noted.
The Pharmaceutical Services Negotiating Committee (PSNC) has expressed its concerns over sustained pressures on medicines supply that are having a very
serious impact on community pharmacy teams and their patients.
It has asked contractors and their teams to continue using its regular reporting tools to help them demonstrate the scale of the problems to the Department of
Health and Social Care (DHSC) and to support escalations as needed.
The committee said: "The sustained increases in price concessions that we have seen so far in 2022 - with more than 100 concessions being granted in some months -
show no signs of abating, and we know that many pharmacies now find themselves in a critical situation trying to source medicines in timely manner and facing
significant financial risk due to greater uncertainty around expected reimbursement prices for a large number of medicines."
"We know that some concessions being imposed by the Department do not match contractors' experience on the ground, and we would ask all contractors to continue
reporting pricing issues to us on a regular basis to support our representations: Report product over Drug Tariff price."
The NHS Business Services Authority (NHSBSA) has published the Drug Tariff Category M price list for July which reflects an increase in reimbursement
level of approximately £5m per quarter.
An adjustment of -£23.8m was announced, in light of the results of the margin survey (latest result up until end of December 2022), and the phasing down of the
additional £100m agreed across years 4 and 5 as part of the Community Pharmacy Contractual Framework and uplifts for underlying market prices
(between January - March 2023).
Community Pharmacy England has agreed the adjustments based on the analysis of margin delivery and on current projections for 2023/24.
It said: "The objectives are to ensure full delivery of agreed margin and smooth delivery as much as possible. As always, the impact on individual pharmacies
will vary depending on dispensing mix."
The Department of Health and Social Care (DHSC) will introduce new arrangements for the setting of Drug Tariff Category A reimbursement prices from April 2024.
Driven by ministers, DHSC's decision aims to equalise access to margin on Category A medicines and it's part of a series of drug reimbursement reforms proposed by
the department following a public consultation in 2019.
Currently, prices of medicines in Category A are subject to monthly adjustment. From 1 April 2024, these will be updated quarterly based on sales and volume data
obtained by DHSC under the Health Service Products (Provision and Disclosure of Information) Regulations 2018. The transition will conclude in July 2025 when the reimbursement prices will be exclusively determined by the new method.
Advance notice for contractors regarding the 'new arrangements' has been outlined on the NHSBSA website.
However, Community Pharmacy England (CPE) did not support the introduction of the changes at this time as pharmacies are currently grappling with "wider challenges"
and there is uncertainty about the potential impact of these changes on the already "turbulent" medicines supply chain
The PSNC on Friday said it has warned the DHSC about the "very serious impact" of the limited supply of certain antibiotics on pharmacies who are "having to
chase stock, purchase without sight of any concession prices, and cope with increasing patient questions and abuse."
With higher than usual number of cases of scarlet fever, caused by invasive Group A Streptococci (iGAS) infections, being reported in children across the country,
supplies of antibiotics for Group A Strep treatment have seen a surge in demand, leading to limited supply at certain wholesalers and pharmacies.
PSNC has urged the DHSC to adopt measures that could help to manage the current crisis, such as allowing pharmacists more freedom to change strengths or formulations
without prescriber approval, outside of Serious Shortage Protocols.
It has also raised concerns on the significant rise in wholesale prices of many oral antibiotics as a result of the surge in demand and the ongoing supply
disruptions. PSNC also said they have received reports of some suppliers putting up their prices for any oral antibiotics they do have in stock.
The Pharmaceutical Services Negotiating Committee (PSNC) has raised concerns over the impact that high medicine price rises are having on contractor.
Recently, the Department of Health and Social Care (DHSC) has granted the final list of price concessions for December 2022. The latest additions bring the total
number of concessionary prices granted for the month of December to 198, surpassing the previous record of 159 granted in September 2022.
PSNC has heard from hundreds of community pharmacy contractors who are paying inflated prices for antibiotics used for the treatment of Strep A and who have rightly
been concerned about the lack of certainty around the final reimbursement prices for these medicines.
It added: "We welcomed the involvement of the Competition and Markets Authority (CMA) to look into the pricing of antibiotics. But the number of reports we are
getting from contractors about medicines price rises are just not acceptable and this goes far beyond the antibiotic crisis."